Yorktown Management & Research Co Inc held its stake in Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,100 shares of the biopharmaceutical company’s stock at the end of the first quarter. Yorktown Management & Research Co Inc’s holdings in Celgene Corporation were worth $261,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the stock. Lyell Wealth Management LP purchased a new position in Celgene Corporation during the fourth quarter valued at approximately $2,015,000. Smith Shellnut Wilson LLC ADV purchased a new position in Celgene Corporation during the fourth quarter valued at approximately $374,000. Bluestein R H & Co. increased its position in Celgene Corporation by 200.0% in the fourth quarter. Bluestein R H & Co. now owns 9,300 shares of the biopharmaceutical company’s stock valued at $1,076,000 after buying an additional 6,200 shares in the last quarter. Diligent Investors LLC purchased a new position in Celgene Corporation during the fourth quarter valued at approximately $375,000. Finally, Monetary Management Group Inc. increased its position in Celgene Corporation by 1.9% in the fourth quarter. Monetary Management Group Inc. now owns 23,740 shares of the biopharmaceutical company’s stock valued at $2,748,000 after buying an additional 435 shares in the last quarter. 78.12% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation (NASDAQ CELG) opened at 132.25 on Wednesday. The company’s 50 day moving average price is $121.46 and its 200 day moving average price is $120.59. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $135.18. The stock has a market cap of $103.26 billion, a PE ratio of 49.66 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.21. Celgene Corporation had a return on equity of 70.94% and a net margin of 18.32%. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.04 billion. During the same quarter last year, the company earned $1.32 EPS. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis. Equities analysts forecast that Celgene Corporation will post $7.29 EPS for the current fiscal year.
Several equities analysts have commented on the company. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and increased their target price for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 target price on shares of Celgene Corporation in a research report on Monday, May 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $139.00 target price on shares of Celgene Corporation in a research report on Thursday, July 6th. Finally, SunTrust Banks, Inc. set a $150.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twenty have given a buy rating and one has given a strong buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and an average price target of $141.04.
In related news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 237,005 shares of company stock valued at $31,515,142. 0.95% of the stock is owned by corporate insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.